DLA Piper advises TD Cowen in Jasper Therapeutics public offering

DLA Piper advised TD Cowen as sole book-running manager in a US$30 million public offering of common stock, pre-funded warrants and common warrants for Jasper Therapeutics, Inc.

Jasper Therapeutics is a clinical-stage biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting KIT (CD117), to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma.

Partner Stephen Alicanti (New York) led the team, which included Partners Lisa Haile (San Diego), Christopher Mikson (Philadelphia), Of Counsel Christie Lehr (Raleigh), and Associates Gina Lee (Raleigh), Alexander Grynszpan, and Angie Franco (both New York).

DLA Piper enables issuers and underwriters to execute complex securities transactions throughout the world. We offer tactical approaches to financings across equity and debt capital markets, alternative public offerings (de-SPACs, reverse mergers, and direct listings), and other transformative corporate transactions. Lawyers in our corporate governance practice act as outside corporate and securities counsel to a wide range of reporting companies by guiding clients through securities offerings and nuanced disclosure, governance, and compliance matters under SEC, Nasdaq, and NYSE rules and regulations. Boards of directors turn to us to navigate complex transactions, special investigations, and challenging risk oversight matters. Please visit Capital Markets and Public Company Advisory and Market Edge.